Replies to post #221583 on Biotech Values

[novicetrader]

SELB...was today's Interim Data for Phase-2 SEL-212 Gout that bad to cause such a big drop?
Or is today's drop a continuation of the Cancer SEL-403 Phase 1 news of last week?
https://finance.yahoo.com/m/8a34a661-6ec0-3d5d-9287-cc48a80678e0/watertown-biotech-selecta.html

[DewDiligence]

SELB +45% on Pompe collaboration with AskBio (private):

https://finance.yahoo.com/news/askbio-licenses-rights-selecta-biosciences-132510864.html

Technically, what happened today was that AskBio exercised its option to license SELB’s platform for development of an AAV-based gene therapy for Pompe disease.

[DewDiligence]

SELB reverse-merges with—(private)—Cartesian Therapeutics:

https://finance.yahoo.com/news/selecta-biosciences-announces-merger-cartesian-130500619.html

Concurrent with the merger, the combined company has been renamed Cartesian Therapeutics, Inc. The Company’s Nasdaq ticker symbol will change to “RNAC” effective prior to the opening of trading tomorrow, November 14, 2023.

…On a pro forma basis… stockholders of Selecta immediately prior to the acquisition will own approximately 26.9% of the Company…

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.